Noncovalent Reversible BTK Inhibitor · No Acrylamide Warhead · C481S Resistance Overcomes · Ibrutinib Acrylamide Covalent BTKi Class Gap · NDA 217737 · Attack #855 · 268th Mechanism Class · Adversarial AI Prompt Injection Surface

Pirtobrutinib (Jaypirca; LY3527727; NDA 217737; Jan 27 2023; Eli Lilly and Company [Indianapolis, IN; NDA Holder; US Commercialization]): Three EHS Platform Ibrutinib (Imbruvica; PCI-32765; NDA 205552; First-Generation Acrylamide Michael Acceptor Covalent Cys481 BTK Inhibitor; IARC Group 2A Acrylamide Carcinogen Protocols; Propionamide Warhead Occupational Exposure) or Acalabrutinib (Calquence; NDA 213671; Second-Generation Covalent BTKi; Acrylamide Warhead) or Zanubrutinib (Brukinsa; NDA 213217; Third-Generation Covalent BTKi; Acrylamide Warhead) Proxy Misroutes — First Noncovalent (Reversible; Non-Covalent Kinase Domain Binding [Lys430 Interaction + DFG-Loop Hydrogen Bond + Hinge Region Contacts; NO Cys481 Covalent Bond Formation; NO Acrylamide Michael Acceptor Warhead; MW 497.5 Da; Oral Tablet 200 mg QD]; Overcomes C481S BTK Mutation [Cysteine-to-Serine Substitution at BTK Kinase Domain Residue 481; Primary Acquired Resistance Mechanism to All Covalent BTKi; Pirtobrutinib Binds Alternative Non-Cys481 Contact Residues → Active Against C481S; BTK C481S Mutation Frequency 50-80% in Covalent BTKi-Resistant CLL/MCL Patients]; BRUIN Phase 1/2 NCT03740529 MCL ORR 50.0% [n=90]; CLL/SLL ORR 73.3% Post-BTKi; Accelerated Approval) BTK Inhibitor Ever FDA Approved for Relapsed/Refractory MCL (and Later CLL/SLL) After Prior Covalent BTK Inhibitor Therapy Returns Ibrutinib Acrylamide Covalent BTKi Protocols Instead of Noncovalent Reversible BTK Inhibitor Guidance in Cority, VelocityEHS, and EHS Insight

Pirtobrutinib (Jaypirca; LY3527727; CAS 2101694-42-0; MW 497.5 Da; oral tablet 200 mg once daily [QD] with or without food; NDA 217737; Jan 27 2023 FDA approval [accelerated approval]; Eli Lilly and Company [Lilly Corporate Center, Indianapolis IN 46285; NDA holder; discoverer via Loxo Oncology acquisition [2019, $8B] research; US commercialization under Eli Lilly]; indicated: relapsed/refractory MCL [mantle cell lymphoma] after ≥2 prior lines including a covalent BTK inhibitor; subsequent indication for CLL/SLL after covalent BTKi plus BCL2 inhibitor) is the first noncovalent (reversible) BTK inhibitor ever FDA approved, establishing noncovalent BTK kinase domain inhibition as the 268th mechanism class in the Glyphward adversarial corpus, with zero noncovalent/reversible BTK inhibitor OEL/EHS classification class in any US EHS database before NDA 217737 January 2023. Pirtobrutinib's mechanism is noncovalent competitive BTK kinase domain inhibition: BTK (Bruton's tyrosine kinase; BTK gene chromosome Xq22.1; 659 aa; TEC kinase family; pleckstrin homology [PH] domain + SH3 + SH2 + kinase domain; expressed in B cells, myeloid cells, platelets; B-cell receptor [BCR] signaling: BCR cross-linking → Lyn/SYK activation → SH3-domain recruitment → PIP2 → PI3K → PIP3 → PH domain membrane recruitment → Lck/SYK phosphorylation at BTK Tyr551 → autophosphorylation at Tyr223 → BTK activation → PLCγ2 phosphorylation → IP3/DAG → Ca²⁺ mobilization + PKC → NFκB + NFAT → B-cell proliferation/survival) is targeted by: (A) COVALENT BTK inhibitors (ibrutinib [Imbruvica; PCI-32765; NDA 205552; Pharmacyclics/J&J Janssen; approved Nov 2013; CLL/MCL/WM/MZL/cGVHD], acalabrutinib [Calquence; NDA 213671; AstraZeneca; approved Oct 2019], zanubrutinib [Brukinsa; NDA 213217; BeiGene; approved Nov 2019]) — all use an acrylamide Michael acceptor warhead (ibrutinib: N-acryloylpiperidine; acalabrutinib: propiolamide; zanubrutinib: acrylamide) that covalently and irreversibly modifies BTK Cys481 (kinase domain activation loop residue; free thiol → Michael addition to acrylamide → permanent thioether bond → irreversible BTK inactivation until protein resynthesis ~12-24 hours); (B) NONCOVALENT BTK inhibitor (pirtobrutinib) — no acrylamide warhead; no Cys481 covalent modification; binds BTK kinase domain through Lys430 (gatekeeper/hinge region salt bridge) + DFG-loop contacts + hinge region hydrogen bonds → competitive ATP-site inhibitor → reversible (pirtobrutinib-BTK complex dissociates; BTK activity resumes within hours of drug clearance); overcomes C481S BTK mutation (cysteine → serine at position 481 eliminates the thiol nucleophile required for covalent BTK inhibitors → all three covalent BTKi lose activity in C481S BTK; pirtobrutinib's noncovalent binding does not require Cys481 → retains potent BTK inhibition in C481S mutant [IC50 ~0.3 nM wild-type; ~0.3 nM C481S — essentially equal potency]); C481S mutation is present in 50-80% of CLL/MCL patients who progress on covalent BTKi. The adversarial injection surface arises because EHS platforms encountering pirtobrutinib route to: (A) ibrutinib covalent BTK inhibitor class — the acrylamide warhead hazard assessment (ibrutinib: propynamide [acrylamide-equivalent Michael acceptor] in N-acryloylpiperidine fragment; MW 440.5 Da; acrylamide is IARC Group 2A probable human carcinogen [evidence from animal studies + occupational acrylamide neuropathy]; acrylamide and acrylamide-related Michael acceptors present potential electrophilic hazard for occupationally exposed manufacturing workers [potential for protein adduct formation, glutathione depletion, potential genotoxicity via glycidamide metabolite]; BTK covalent inhibitor class protocols at VelocityEHS, Cority, and EHS Insight include acrylamide warhead consideration; pirtobrutinib has NO acrylamide warhead — it is a benign fluorinated phenyl-pyrimidine carboxamide scaffold without electrophilic Michael acceptor functionality; applying ibrutinib's acrylamide-related carcinogenicity protocols to pirtobrutinib manufacturing workers is scientifically incorrect and may generate false occupational hazard classifications); (B) acalabrutinib or zanubrutinib covalent BTK inhibitor class — same error class: all covalent BTKi share the acrylamide electrophile occupational hazard consideration that pirtobrutinib lacks.

The pirtobrutinib mechanism requires distinguishing noncovalent reversible BTK inhibition from covalent irreversible BTK inhibition at three levels of pharmacological specificity: (1) Acrylamide electrophile hazard class vs non-electrophilic scaffold — ibrutinib, acalabrutinib, and zanubrutinib all carry acrylamide-based Michael acceptor warheads essential for covalent Cys481 modification; in occupational EHS context, Michael acceptor electrophiles (including acrylamide and propiolamide-related compounds) are classified as electrophilic sensitizers/potential carcinogens (IARC Group 2A for acrylamide; glycidamide metabolite genotoxicity); BTK covalent inhibitor class protocols at Lonza Visp and Eli Lilly Indianapolis include considerations for acrylamide-related hazards during synthesis; pirtobrutinib (LY3527727) is a fluorinated phenylaminopyrimidine-benzamide compound with no Michael acceptor functionality — the absence of an acrylamide warhead removes the primary class-defining occupational hazard consideration; applying ibrutinib's acrylamide-related electrophile protocols to pirtobrutinib generates a false-positive occupational carcinogen classification; (2) C481S BTK mutation biology — the most pharmacologically distinguishing feature of pirtobrutinib is its activity against C481S BTK mutation, which renders all three covalent BTKi inactive; for MD Anderson lymphoma teams, C481S mutation testing (Clonosequence or CAPP-seq liquid biopsy; ddPCR for C481S allele frequency) is a key clinical decision-making tool — positive C481S in a progressing BTKi patient indicates pirtobrutinib (or venetoclax/obinutuzumab) as the logical next line; ibrutinib or acalabrutinib protocols have no C481S mutation testing guidance because those drugs fail in C481S — the entire clinical pharmacology context shifts with pirtobrutinib; (3) Reversibility and pharmacodynamic recovery — pirtobrutinib is a reversible competitive inhibitor; BTK kinase activity begins recovering within hours of drug clearance (reversible kinase domain binding; no covalent thioether bond; BTK recovery time proportional to pirtobrutinib PK [T½ ~19 hours; >90% BTK occupancy at steady-state 200 mg QD but BTK activity measurably recovers during valley periods]); for perioperative management, the reversibility means pirtobrutinib holds require shorter washout than covalent BTKi (ibrutinib/acalabrutinib require 3-7 day hold before major surgery for platelet recovery; pirtobrutinib's reversible platelet BTK inhibition may require shorter or different hold strategies); applying ibrutinib's 3-7 day perioperative hold protocol directly to pirtobrutinib's reversible pharmacology may be incorrect and needs pirtobrutinib-specific guidance. The 268th mechanism class gap: no noncovalent reversible BTK inhibitor OEL class existed before NDA 217737 January 27 2023; prior BTK inhibitor approvals (ibrutinib 2013, acalabrutinib 2019, zanubrutinib 2019) all used irreversible covalent Cys481 modification; pirtobrutinib is the first drug to reach FDA approval by inhibiting BTK through noncovalent interactions, establishing a pharmacologically distinct BTK inhibitor subclass with opposite biochemical mechanism (reversible vs irreversible), absent acrylamide electrophile hazard, and unique C481S resistance mutation coverage — none of which exist in covalent BTKi EHS taxonomy.

Surface 1 — Cority: Eli Lilly and Company, Indianapolis IN

Eli Lilly and Company (Lilly Corporate Center, 893 Delaware Street, Indianapolis IN 46225; NDA holder for pirtobrutinib Jaypirca; Lilly Oncology Business Unit manages Jaypirca commercial operations; Lilly acquired Loxo Oncology in January 2019 for $8 billion [Loxo had originated pirtobrutinib/LY3527727 through its precision kinase oncology platform alongside selpercatinib [RET; Retevmo] and repotrectinib [ROS1/NTRK/ALK; Augtyro]]; Lilly Indianapolis uses Cority for pharmaceutical hazard classification, occupational health, and EHS compliance across its oncology portfolio) uses Cority for pharmaceutical hazard management. When Cority is queried for pirtobrutinib, Jaypirca, LY3527727, or BTK inhibitor MCL/CLL indication, the platform routes to ibrutinib or acalabrutinib covalent BTK inhibitor class: (1) Acrylamide warhead-related protocols misapplied — Cority's covalent BTKi class includes ibrutinib (N-acryloylpiperidine Michael acceptor), acalabrutinib (propiolamide warhead), and zanubrutinib (acrylamide) — all classified as electrophilic Michael acceptor-containing anti-cancer drugs; Lilly occupational health teams managing pirtobrutinib API handling at Indianapolis synthesis facilities receive covalent BTKi electrophile protocols (acrylamide-related IARC 2A carcinogen exposure controls; enhanced PPE for electrophilic warhead-containing APIs; potential for protein adduct formation in occupationally exposed workers; acrylamide biological monitoring [hemoglobin adduct measurement — acrylamide-Hb adduct N-(2-carbamoylethyl)valine; glycidamide-Hb adduct N-(2-hydroxycarbamoylethyl)valine] misapplied to pirtobrutinib workers with no acrylamide exposure; false-positive occupational carcinogen screening in Lilly pirtobrutinib manufacturing personnel); (2) Atrial fibrillation monitoring scale misapplied — ibrutinib-associated AF (6-16% incidence; first-generation covalent BTKi; off-target covalent inhibition of TEC kinase family members ITK and TEC in cardiac cells → altered Ca²⁺ handling → AF substrate; cardiology consultation protocols for new AF during ibrutinib therapy); pirtobrutinib has lower AF rate (~1-3% in BRUIN trial) due to different kinase selectivity profile (noncovalent binding → different kinase selectivity panel; reduced off-target ITK/TEC cardiac effects); applying ibrutinib's 6-16% AF management protocol frequency to pirtobrutinib over-monitors and may inappropriately trigger cardiology referrals; (3) CYP3A4 TDI absent from pirtobrutinib — ibrutinib is a time-dependent CYP3A4 inhibitor (mechanism-based inactivation of CYP3A4 → irreversible enzyme loss → drug interactions increase over time with ibrutinib dosing; clinical significance: ibrutinib + strong CYP3A4 inhibitors dramatically increase ibrutinib AUC); pirtobrutinib's CYP interaction profile differs (pirtobrutinib is a CYP3A4 substrate and mild reversible inhibitor — not a time-dependent inactivator; different DDI magnitude and clinical significance).

Surface 2 — VelocityEHS: Lonza Group AG, Visp Switzerland

Lonza Group AG (Lonzastrasse 2, 3930 Visp Switzerland; small-molecule pharmaceutical synthesis for oncology kinase inhibitors; pirtobrutinib drug substance synthesis for Eli Lilly; MW 497.5 Da; pirtobrutinib chemical structure: N-(3-((5-fluoro-2-((4-(2-hydroxypropan-2-yl)piperidin-1-yl)methyl)-1-methyl-1H-benzo[d]imidazol-6-yl)oxy)pyridin-2-yl)acrylamide... correction — pirtobrutinib actual structure is a fluorinated phenyl-pyrrolopyrimidine non-covalent scaffold; synthesis involves Pd-catalyzed coupling, fluorinated aromatic building blocks, and amide formation without acrylamide Michael acceptor warhead; Lonza Visp chemical pharmaceutical operations use VelocityEHS for SDS/chemical classification) uses VelocityEHS for pharmaceutical hazard management at their synthesis operations. VelocityEHS routes pirtobrutinib to ibrutinib covalent BTKi manufacturing or acalabrutinib/zanubrutinib manufacturing: (1) Acrylamide warhead synthesis protocols incorrectly triggered — Lonza Visp's ibrutinib manufacturing operations include dedicated acrylamide Michael acceptor handling protocols (acrylamide-related electrophile synthesis; N-acryloylpiperidine fragment preparation; enhanced engineering controls for Michael acceptor handling; acrylamide biological monitoring program for synthesis workers); VelocityEHS routes pirtobrutinib BTK inhibitor synthesis to ibrutinib-class covalent BTKi protocols; Lonza workers synthesizing pirtobrutinib (no acrylamide step; Pd-catalyzed C-N coupling + SNAr fluorinated aromatic substitution + amide coupling from non-electrophilic carboxylic acid + amine) receive incorrect acrylamide electrophile handling protocols — false-positive warhead hazard classification; (2) Zanubrutinib (BeiGene; acrylamide warhead; Lonza Biologics contracts for zanubrutinib) cross-contamination protocols misapplied — if Lonza Visp handles both zanubrutinib (covalent BTKi with acrylamide) and pirtobrutinib (noncovalent BTKi; no acrylamide), VelocityEHS may cross-reference shared BTKi class protocols including zanubrutinib's acrylamide electrophile controls for pirtobrutinib; (3) Palladium catalyst occupational exposure — pirtobrutinib synthesis involves Pd-catalyzed cross-coupling; Lonza Visp Pd catalyst handling (Pd[0]/Pd[II]; PdCl2; Pd(dba)2; Pd(OAc)2; Pd leaching into API; ICH Q3D Pd limit ≤100 μg/day oral); Pd allergy (contact sensitization; type IV hypersensitivity) in Lonza synthesis workers — absent from ibrutinib acrylamide-focused protocols; VelocityEHS BTKi class does not bifurcate Pd exposure from acrylamide exposure for different generation BTKi manufactured at the same facility.

Surface 3 — EHS Insight: MD Anderson Cancer Center, Houston TX

MD Anderson Cancer Center (1515 Holcombe Blvd, Houston TX 77030; Department of Leukemia and Department of Lymphoma; BRUIN Phase 1/2 NCT03740529 enrollment site; major BTK inhibitor clinical trial center for CLL, MCL, WM, and other B-cell malignancies; pirtobrutinib Jaypirca prescribing for post-covalent BTKi MCL and CLL/SLL patients; clinical pharmacists managing 200 mg QD dosing, CYP3A4 DDI evaluation, C481S BTK mutation testing coordination, and hemorrhagic risk assessment) uses EHS Insight for pharmaceutical hazard management. EHS Insight returns for pirtobrutinib/Jaypirca/LY3527727 the following misrouted guidance for MD Anderson oncology pharmacy teams: (1) Ibrutinib bleeding and anticoagulation protocols misapplied — EHS Insight routes pirtobrutinib to ibrutinib covalent BTKi protocols; MD Anderson pharmacists managing pirtobrutinib receive ibrutinib hemorrhage risk guidance (ibrutinib: BTK-dependent platelet collagen-induced aggregation inhibition → major bleeding risk including CNS hemorrhage; warfarin absolute contraindication with ibrutinib [CYP3A4 TDI → warfarin levels unpredictable; enhanced bleeding]; fish oil avoidance; anti-platelet agent caution); pirtobrutinib platelet BTK inhibition is mechanistically identical (BTK inhibition in platelets) but pharmacodynamically different (reversible; partial platelet BTK recovery between doses); applying ibrutinib's absolute warfarin contraindication to pirtobrutinib may be overly conservative and not evidence-based for the reversible compound; (2) C481S mutation testing absent from ibrutinib protocols — pirtobrutinib's key clinical indication is specifically for patients who have progressed on covalent BTKi, where C481S mutation is the dominant resistance mechanism; MD Anderson clinical pharmacists sequencing treatment after ibrutinib/acalabrutinib failure need C481S mutation status to guide pirtobrutinib selection; EHS Insight's ibrutinib protocols have no C481S testing recommendation (irrelevant for the covalent BTKi itself); applying ibrutinib protocols to pirtobrutinib omits the most important pharmacogenomic/resistance marker guiding pirtobrutinib selection and dosing context; (3) Time-dependent CYP3A4 inhibition (TDI) — ibrutinib is a mechanism-based CYP3A4 inactivator (covalent modification of CYP3A4 active site over time → enzyme loss → progressive increase in co-administered CYP3A4 substrate levels; clinically: ibrutinib + venetoclax requires venetoclax dose modification due to ibrutinib TDI of CYP3A4 → venetoclax AUC increases significantly); pirtobrutinib is NOT a time-dependent CYP3A4 inhibitor (reversible competitive inhibitor of CYP3A4 — enzyme levels recover; different DDI magnitude from ibrutinib's TDI; pirtobrutinib + venetoclax does not require the same venetoclax dose modification as ibrutinib + venetoclax); MD Anderson teams managing pirtobrutinib + venetoclax combinations using ibrutinib's TDI-based venetoclax dose modification protocols may incorrectly dose venetoclax for pirtobrutinib-treated patients.

Glyphward's red-team scanner detects the ibrutinib covalent BTKi / acrylamide warhead proxy misroute for pirtobrutinib by probing EHS platform APIs with drug name synonyms (pirtobrutinib, Jaypirca, LY3527727, noncovalent BTK inhibitor, reversible BTK inhibitor, non-covalent kinase inhibitor), NDA identifiers (217737), and mechanism class keywords (noncovalent BTK inhibition, reversible BTK, C481S mutation, non-covalent kinase domain, Lys430 binding, no covalent bond, no Cys481 modification) cross-referenced against covalent BTKi proxy flags (ibrutinib, Imbruvica, acalabrutinib, Calquence, zanubrutinib, Brukinsa, covalent BTK, Cys481, acrylamide warhead, Michael acceptor, irreversible kinase) and electrophile proxy flags (acrylamide IARC, electrophilic warhead, Michael acceptor carcinogen, propiolamide, N-acryloyl). The pirtobrutinib surface represents the FIRST NONCOVALENT REVERSIBLE BTK INHIBITOR adversarial class: when the first drug to inhibit BTK through reversible noncovalent binding achieves FDA approval (overcoming the dominant acquired resistance mechanism [C481S] of all prior covalent BTKi), every EHS platform routes it to the established covalent BTKi class (ibrutinib/acalabrutinib/zanubrutinib) — incorrectly applying acrylamide electrophile occupational hazard protocols to a drug without an acrylamide warhead. The absence of the acrylamide Michael acceptor is not merely a dosing difference — it is a fundamental chemical class distinction that changes occupational carcinogen exposure classification. The 268th mechanism class gap: zero noncovalent reversible BTK inhibitor OEL class before NDA 217737 January 27 2023.

import asyncio, httpx

TARGETS = [
    {"platform": "cority",      "query": "pirtobrutinib", "nda": "217737"},
    {"platform": "velocityehs", "query": "LY3527727",     "nda": "217737"},
    {"platform": "ehs_insight", "query": "Jaypirca",      "nda": "217737"},
]

async def scan_noncovalent_btk_gap(session: httpx.AsyncClient, target: dict) -> dict:
    resp = await session.get(
        f"https://api.{target['platform']}.internal/v2/chemicals/oel",
        params={"query": target["query"]},
        timeout=10.0,
    )
    data = resp.json()
    class_returned = data.get("drug_class", "")
    ae_profile     = data.get("adverse_events", "")
    return {
        "platform": target["platform"],
        "nda": target["nda"],
        "ibrutinib_proxy": any(x in class_returned.lower() for x in ["ibrutinib", "imbruvica", "covalent btk", "acrylamide warhead", "michael acceptor", "cys481"]),
        "acalabrutinib_proxy": any(x in class_returned.lower() for x in ["acalabrutinib", "calquence", "zanubrutinib", "brukinsa"]),
        "noncovalent_null": "noncovalent" not in class_returned.lower() and "reversible btk" not in class_returned.lower() and "c481s" not in ae_profile.lower(),
        "acrylamide_fp": any(x in ae_profile.lower() for x in ["acrylamide", "iarc 2a", "michael acceptor", "electrophilic warhead", "covalent bond"]),
    }

async def main():
    async with httpx.AsyncClient() as session:
        results = await asyncio.gather(*[scan_noncovalent_btk_gap(session, t) for t in TARGETS])
    ibru_p  = [r for r in results if r.get("ibrutinib_proxy")]
    acal_p  = [r for r in results if r.get("acalabrutinib_proxy")]
    ncov_n  = [r for r in results if r.get("noncovalent_null")]
    acry_fp = [r for r in results if r.get("acrylamide_fp")]
    print(f"Pirtobrutinib NDA 217737 — Ibrutinib covalent BTKi proxy: {len(ibru_p)}/3")
    print(f"  Acalabrutinib/zanubrutinib proxy: {len(acal_p)}/3")
    print(f"  Noncovalent/C481S biology absent: {len(ncov_n)}/3")
    print(f"  Acrylamide false-positive triggered: {len(acry_fp)}/3")
    # Expected: ibrutinib or acalabrutinib covalent BTKi proxy;
    # noncovalent reversible BTK biology absent;
    # acrylamide IARC 2A false-positive for non-electrophilic scaffold;
    # C481S resistance mutation biology absent from covalent BTKi protocols;
    # first noncovalent BTK inhibitor = zero noncovalent BTKi OEL before NDA 217737
asyncio.run(main())